Buzz Hollander
Viewpoint: Lecanemab — Will this ‘promising’ new Alzheimer’s drug deliver on the hype?
You may have heard: AN ALZHEIMER’S DRUG ACTUALLY HAD A POSITIVE TRIAL!!! The news on Biogen/Eisai’s lecanemab was “exciting,” “shocking,” ...
Viewpoint: Splenda scare? Should we be concerned about reports linking artificial sweeteners to strokes?
I’ve learned to allow my patients to have strange tastes in beverages. Should I be tolerant towards their drive to ...
Polio was found in New York City wastewater. Should we brace for another epidemic?
It’s easy to feel a bit of panic in the air. A young man was paralyzed in the New York ...
Viewpoint: ‘Unfettered optimism’? A tiny cancer trial reports a ‘100% cure rate’ with immunotherapy — but are headlines overstating the promise?
When the New York Times tripped off a cascade of upbeat stories this week with its reporting on a 100% ...
Viewpoint: Why we should be cautious about injectable weight loss drugs
This headline caught my attention: “Experimental Weight-Loss Drug Shows Surgery-Like Results”. This new med, tirzepatide, a once-weekly injectable, will probably ...
Some patients who take COVID medication Paxlovid experience rebound symptom recurrence
I had low expectations for Pfizer’s anti-Covid medication, Paxlovid, before its clinical trial data was released. After all, novel antivirals ...
